Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema

Core Insights - Sanofi's amlitelimab drug has demonstrated its potential to treat eczema in patients aged 12 years and older through two late-phase studies [1] Group 1 - The drug's efficacy was confirmed in late-phase studies, indicating a significant advancement in eczema treatment options for adolescents and adults [1]